At the 14th St. Gallen International Breast Cancer Conference 2015, Dr John Bartlett (Ontario Institute for Cancer Research, Toronto, Canada) discusses his study on the influence of cut points for the proliferation marker, Ki67, in clinical decision-making in breast cancer patients, and suggests that Ki67 could be used as a continuous marker in this setting.
Ki67 as a marker for making management decisions in breast cancer
24th April 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?